SHINE Technologies, LLC, a next-generation fusion technology company, announced that Harrie Buurlage has been named Chief Commercial Officer of Isotopes.
Buurlage, who has been the General Manager of SHINE Europe since 2019, will now oversee all commercial aspects of SHINE’s therapeutic and diagnostic medical isotope divisions. Supporting Buurlage in driving the growth of SHINE’s medical isotope business will be Magdalena Brzezowska, a proven leader with extensive commercial experience in radiopharmaceuticals, who has been named Vice President of Sales and Business Development, the statement said.
Buurlage’s experience includes three decades in the nuclear medicine industry, encompassing management and marketing roles. He was the Chief Operating Officer at NRG in the Netherlands, overseeing key nuclear installations, and the global director for nuclear manufacturing at Covidien USA, now Curium Pharma. With 15 years at Mallinckrodt and an applied physics background from the University of Groningen, he also holds Europe’s highest certification, the senior radiation safety officer from the University of Leiden, qualifying him to supervise complex nuclear sites.
“We are on the cusp of dramatically altering the global medical isotope supply chain , so it only makes sense to have one of the world’s more experienced business leaders in nuclear medicine at the helm,” said Greg Piefer, founder and CEO of SHINE. “Harrie has been a key member of my team over the past four years, and we’re excited to leverage his growth experience and industry expertise as we bring North America’s largest lutetium-177 production facility online.”
“SHINE is well-positioned to provide increased access to life-saving medicine, and I look forward to helping usher in the next era of medical isotope production,” Buurlage said. “What we are doing is vitally important to patients needing diagnosis and treatment of cancer and illnesses around the globe.”
